We've found
45,497
archived clinical trials in
Breast Cancer
We've found
45,497
archived clinical trials in
Breast Cancer
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Updated: 12/31/1969
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Updated: 12/31/1969
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
Updated: 12/31/1969
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
Updated: 12/31/1969
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Updated: 12/31/1969
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials